Brief: Arca Biopharma Q3 Loss Per Share $0.33

Oruka Therapeutics

02/11/2020 14:05

Nov 2 (Reuters) - ARCA Biopharma Inc  ABIO.O :
    * ARCA BIOPHARMA ANNOUNCES THIRD QUARTER 2020 FINANCIAL
RESULTS 
AND PROVIDES CORPORATE UPDATE
    * Q3 LOSS PER SHARE $0.33
    * INITIATION OF PHASE 2B CLINICAL TRIAL EVALUATING AB201 AS
A
POTENTIAL TREATMENT FOR COVID19 ANTICIPATED IN Q4
    * CASH AND CASH EQUIVALENTS WERE $51.1 MILLION AS OF
SEPTEMBER 30,
2020
    * BELIEVES THAT ITS CURRENT CASH AND CASH EQUIVALENTS WILL
BE
SUFFICIENT TO FUND ITS OPERATIONS THROUGH 2022

Source text for Eikon:  ID:nGNX4sL52v 
Further company coverage:  ABIO.O 

 ((Reuters.Briefs@thomsonreuters.com;))